AstraZeneca (LON: AZN) Halts Phase 3 Lung Cancer Trial After Volrustomig Fails to Show Survival Benefit

AstraZeneca has halted a late-stage trial of its lung cancer drug Volrustomig, marking a fresh pipeline setback. The FTSE 100 company said the drug, combined with chemotherapy, was unlikely to improve survival rates. An Independent Data Monitoring Committee recommended stopping the Phase 3 trial after a planned review. 

This marks AstraZeneca’s second major trial halt in just over a month. Shares still traded 1.40% higher at 11,620.00 pence on Monday, August 17, 2026.

AstraZeneca Faces Its Second Trial Setback in Weeks

AstraZeneca’s Volrustomig halt follows a similarly disappointing trial outcome for its heart disease drug Wainua in July 2026. That earlier setback wiped billions off the company’s market value at the time.

• Susan Galbraith, Executive Vice President of Oncology and Hematology R&D, expressed disappointment over the decision.
• She confirmed AstraZeneca remains “determined to continue pioneering new medicines” from its broader oncology pipeline.

Lung cancer remains the biggest cause of cancer death worldwide, making this trial’s outcome particularly significant. AstraZeneca will now shift its Volrustomig development focus toward other cancer types entirely.

What Happens Next for Volrustomig’s Development

AstraZeneca confirmed it will continue testing Volrustomig across several other cancer indications despite this lung cancer setback. The company hasn’t abandoned the drug’s broader development program following the trial halt.

AstraZeneca ditches lung cancer treatment trial https://t.co/Rjj2KF7sBA pic.twitter.com/UUa36XexQP

— The Independent (@Independent) August 17, 2026

• Ongoing trials will continue for cervical cancer and mesothelioma.
• Head and neck squamous cell carcinoma remains another active target for the drug.

This diversified pipeline strategy limits AstraZeneca’s exposure to any single trial failure. Analysts note that spreading Volrustomig across multiple cancer types provides some cushion against Monday’s disappointing lung cancer result.

Enhertu Data Offers a Counterbalance This Week

AstraZeneca also reported encouraging news alongside the Volrustomig halt, involving its existing cancer treatment Enhertu. The drug showed a statistically significant, clinically meaningful improvement in progression-free survival.

• That benefit applied specifically to non-small cell lung cancer patients in a recent trial.
• Enhertu, developed with partner Daiichi Sankyo, will now advance into a Phase 3 trial.

This positive Enhertu data likely helped offset investor concerns following the Volrustomig announcement. AstraZeneca’s stock gain Monday suggests markets weighted the mixed pipeline news relatively evenly overall.

Stock Performance Reflects a Turbulent August

AstraZeneca shares have faced considerable volatility this month, tied to both trial results and merger speculation. The stock traded between 11,546.00 and 11,690.00 pence Monday morning on the London Stock Exchange.

Reports earlier this month suggested AstraZeneca held early-stage merger talks with Bristol Myers Squibb, valued near $400 billion. Investor backlash reportedly killed those discussions by August 11, according to Financial Times reporting. AstraZeneca’s next scheduled earnings report is expected around November 6, 2026.

Our Take

AstraZeneca’s Volrustomig halt adds to a challenging month, but Enhertu’s positive data and a resilient share price suggest investors see the broader pipeline as intact. Continued trials across cervical, head and neck, and mesothelioma cancers keep Volrustomig’s long-term potential alive.

Disclaimer:

The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.